Equities

Tissue Repair Ltd

TRP:ASX

Tissue Repair Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.235
  • Today's Change0.00 / 0.00%
  • Shares traded13.94k
  • 1 Year change-18.97%
  • Beta--
Data delayed at least 20 minutes, as of May 29 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.

  • Revenue in AUD (TTM)457.52k
  • Net income in AUD-3.28m
  • Incorporated2012
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avecho Biotechnology Ltd473.55k-3.44m9.51m29.00--1.49--20.08-0.0016-0.00160.00020.0020.08882.070.5132---64.45-47.08-75.73-55.25-9.2578.67-725.70-156.438.19--0.0267---58.07-19.42-46.71------
TrivarX Ltd20.81k-3.74m10.65m4.00--1.05--511.82-0.0182-0.01820.000090.02490.0023-------42.02-41.56-47.15-50.51100.0092.74-17,949.78-334.16---147.210.0072---4.69-18.0675.85------
BTC Health Ltd16.03k-8.26m11.67m1.00--2.167.07727.91-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Nyrada Inc3.08m-4.98m11.84m----2.25--3.84-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Bioxyne Ltd8.65m-14.17m12.28m16.00--3.94--1.42-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Tissue Repair Ltd457.52k-3.28m12.70m----0.7373--27.75-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Firebrick Pharma Ltd0.00-4.57m13.09m----7.51-----0.0266-0.02660.000.00890.00-------120.70---136.04----------4.37--0.00---79.85---79.18------
Argent BioPharma Ltd1.32m-17.02m13.58m----8.07--10.26-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Radiopharm Theranostics Ltd0.00-46.82m13.81m----0.4601-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Chimeric Therapeutics Ltd0.00-11.31m14.67m----0.8901-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Medlab Clinical Ltd366.64k-3.94m15.07m14.00------41.11-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Calmer Co International Ltd2.46m-4.50m15.09m--------6.13-0.0083-0.00830.0039-0.00050.6551.349.62---119.81-139.15-231.33-198.5536.0330.26-182.94-388.810.482-9.361.22---13.00239.4311.40------
Adalta Ltd3.56m-5.04m15.49m----5.65--4.35-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Lumos Diagnostics Holdings Ltd12.38m-13.29m15.88m----1.14--1.28-0.0357-0.03570.03520.02890.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Rhythm Biosciences Ltd157.67k-8.63m16.41m----11.99--104.06-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Data as of May 29 2024. Currency figures normalised to Tissue Repair Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.